Clinical trial · Interventional
Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer
Quadrimodal Radiological Prediction (Ultrasound, Angiography/Mammography, Magnetic Rsonance Imaging, Positron Emission Tomography-computed Tomgraphy Scan) of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Triple Negative Breast Cancer | Triple-Negative Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imaging assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PRECISION ARM
- description
- Patient will have four imaging exam : MRI, PET-scan, ultrasound and angio/Mammography
- interventionNames
- Other: Imaging assessment
Primary outcomes (1)
- measure
- concordance rate between quadrimodal radiological assessment (ultrasound, angiography/mammography, MRI, PET-CT) and histologically-obtained response following neoadjuvant chemo-immunotherapy in patients with triple-negative breast cancer (TNBC).
- timeFrame
- two weeks after surgery
- description
- concordance of the response between radiological assessement and histological response
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Signed informed consent * Patient with histologically proven TNBC * Indication for neo-adjuvant chemo-immunotherapy treatment * Age between 18 and 75 * Affiliated or beneficiary of a social protection scheme Exclusion Criteria: * Pregnant or breast-feeding women * Contraindication to immunotherapy * Inflammatory breast cancer (T4d) * Metastatic patients * Allergies to iodine or gadolinium * Patient with an augmentation prosthesis (for angiography/mammography) * Claustrophobic patients * Renal contraindication to contrast products according to SFR-CIRTACI * Ferromagnetic material * Uncontrolled diabetes (blood glucose \>10 mmol/L) * Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.). * Patient under guardianship, curatorship or safeguard of justice
References
Publications (0)
Data not yet available